Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Lexicon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for patients with serious diseases, particularly in cardiometabolic and oncology-related conditions. The company operates within the biotechnology and pharmaceutical industries, with a strategy centered on translating genetic insights into first-in-class or best-in-class therapies.
The company’s primary revenue drivers are royalty income and milestone payments from partnered products and the advancement of its proprietary drug candidates. Lexicon is best known for XERMELO® (telotristat ethyl), a treatment for carcinoid syndrome diarrhea, and sotagliflozin, a dual SGLT1/SGLT2 inhibitor developed for heart failure and diabetes-related indications. Founded in 1995, Lexicon initially focused on gene knockout technology and functional genomics before evolving into a late-stage drug development company with commercial-stage assets through strategic partnerships.
Business Operations
Lexicon’s operations are organized around drug discovery, clinical development, and partner-supported commercialization. The company generates revenue primarily through royalties, license fees, and milestone payments tied to partnered products, rather than direct large-scale commercial sales. XERMELO®, discovered by Lexicon, is commercialized in the United States by Lexicon Pharmaceuticals and outside the U.S. by Ipsen, providing ongoing royalty income.
The company maintains domestic operations in the United States, with research and development activities supported by internal scientific teams and external contract research organizations. Lexicon controls a proprietary pipeline of small-molecule therapies, with sotagliflozin representing its most advanced cardiometabolic asset. Manufacturing and late-stage commercialization activities are largely handled through strategic partners rather than fully integrated internal infrastructure.
Strategic Position & Investments
Lexicon’s strategic direction emphasizes maximizing the value of late-stage assets through regulatory approvals, geographic expansion via partnerships, and lifecycle management. A key strategic investment has been the continued development of sotagliflozin, including large-scale cardiovascular outcomes trials targeting heart failure and chronic kidney disease populations. While sotagliflozin has received regulatory approvals in certain international markets, its regulatory status has varied by jurisdiction, and some outcomes remain subject to ongoing regulatory review.
The company has historically pursued a capital-efficient partnership model, exemplified by its collaboration with Ipsen for XERMELO® outside the U.S. Lexicon’s portfolio also includes earlier-stage programs targeting metabolic and rare diseases, reflecting its continued investment in genetically validated targets and differentiated mechanisms of action.
Geographic Footprint
Lexicon Pharmaceuticals is headquartered in The Woodlands, Texas, and its primary operational footprint is in North America. Research, development, and corporate management activities are largely centralized in the United States, while clinical trials are conducted across multiple international regions depending on study design and regulatory requirements.
Through licensing and commercialization partners, Lexicon maintains an indirect presence in Europe, Asia, and other global markets. International influence is primarily driven by partnered product sales, regulatory filings, and multinational clinical development programs rather than wholly owned foreign subsidiaries or large overseas facilities.
Leadership & Governance
Lexicon is led by an executive team with experience in pharmaceutical development, regulatory strategy, and capital markets. The leadership philosophy emphasizes scientific rigor, disciplined capital allocation, and partnership-driven commercialization to manage risk while advancing innovative therapies.
Key executives include:
- Lonnel Coats – President and Chief Executive Officer
- Brian J. Zambrowicz – Founder and Executive Vice President, Research
- Scott E. Coats – Senior Vice President and Chief Financial Officer
- Michael J. Saporito – Senior Vice President and Chief Medical Officer
- Jeffrey L. Wade – Senior Vice President, Chief Legal Officer and Secretary
The company is governed by a board of directors composed of executives and independent members with backgrounds in biotechnology, finance, and corporate governance, aligning oversight with long-term shareholder and patient interests.